Lupus Erythematosus, Cutaneous: all 67 studies

Page 1 of 1. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.

• This Study Will Evaluate the Effect and Safety of 626 in Patients With CLENot yet recruitingNCT07900867Phase 2
• Study of Afimetoran in Adults With Cutaneous Lupus ErythematosusRecruitingNCT07881120Phase 2/3
• A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]RecruitingNCT07840287Phase 3
• A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy AdultsRecruitingNCT07749651Phase 1
• A Study of Quinacrine in Participants With Cutaneous Lupus ErythematosusRecruitingNCT07694336Phase 2
• Study of S-4321 in Participants With an Autoimmune or Immune-mediated DiseaseRecruitingNCT07455578Phase 1
• Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind StudyRecruitingNCT07440537Phase 2
• Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants..Not yet recruitingNCT07408908Phase 1
• A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)RecruitingNCT07355218Phase 3
• A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseaseRecruitingNCT07332481Phase 3
• The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLENot yet recruitingNCT07306585Phase 1
• Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus ErythematosusNot yet recruitingNCT06965244Phase 3
• Research Accelerated by You Lupus RegistryRecruitingNCT06927219
• Tapinarof for Cutaneous Lupus ErythematosusEnrolling by invitationNCT06661213Early Phase 1
• A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE ParticipantsRecruitingNCT06625671Phase 1/2
• Deep Phenotyping of Cutaneous Lupus ErythematosusRecruitingNCT06411106Not applicable
• A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusEnrolling by invitationNCT06044337Phase 3
• Prevalence and Clinical Severity of Cutaneous Lupus ErythematosusRecruitingNCT01510067
• A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.TerminatedNCT05879718Phase 2Results posted
• The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)CompletedNCT05162586Phase 2Results posted
• A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)Active, not recruitingNCT04857034Phase 2Results posted
• Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)TerminatedNCT04809623Phase 1Results posted
• Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus ErythematosusCompletedNCT04781816Phase 2Results posted
• Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)CompletedNCT03134222Phase 2Results posted
• Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus SubjectsCompletedNCT02927457Phase 1Results posted
• Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)CompletedNCT02847598Phase 2Results posted
• Autologous Polyclonal Tregs for LupusTerminatedNCT02428309Phase 1Results posted
• IVIg Efficacy Study to Treat Cutaneous Lupus ErythematosusCompletedNCT01841619Early Phase 1Results posted
• Low-dose UVA1 Radiation in Cutaneous Lupus PatientsCompletedNCT01776190Not applicableResults posted
• Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus ErythematosusCompletedNCT01629784Not applicableResults posted
• Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)CompletedNCT00633945Not applicableResults posted
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus ErythematosusActive, not recruitingNCT07260877Phase 2
• Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy ParticipantsCompletedNCT07072611Early Phase 1
• A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)Active, not recruitingNCT06980805Phase 2
• A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus ErythematosusActive, not recruitingNCT06015737Phase 3
• A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of LupusCompletedNCT06013995Phase 1
• Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)TerminatedNCT05629208Phase 2
• Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus ErythematosusTerminatedNCT05591222Phase 2
• The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)Active, not recruitingNCT05540327Phase 2
• A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusActive, not recruitingNCT05531565Phase 2/3
• A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus ErythematosusCompletedNCT05411016Phase 1
• Efficacy of Fractional Er:YAG Laser in Lupus Erythematosus ScarsWithdrawnNCT04707924Not applicable
• Study of M5049 in CLE and SLE ParticipantsCompletedNCT04647708Phase 1
• A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus ErythematosusCompletedNCT04493541Phase 1
• A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and DermatomyositisCompletedNCT03817424Phase 1
• Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus ErythematosusStatus unknownNCT03260166Phase 2
• Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus ErythematosusCompletedNCT02656082Phase 2
• Pilot Tape Harvesting StudyCompletedNCT02125695
• A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy VolunteersCompletedNCT02034344
• A Non-drug Study Profiling Cutaneous LupusCompletedNCT01923415
• Phase Ib Study of SC Milatuzumab in SLECompletedNCT01845740Phase 1
• A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus ErythematosusCompletedNCT01702740Phase 1
• Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous PemphigoidTerminatedNCT01559155
• Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin LesionCompletedNCT01551069Phase 3
• Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous LupusTerminatedNCT01498406Phase 2
• A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus ErythematosusTerminatedNCT01470313Phase 1
• Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus ErythematosusTerminatedNCT01407679Phase 2
• Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus ErythematosusCompletedNCT01352988Phase 2
• To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus ErythematosusCompletedNCT01300208Phase 2
• Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus ErythematosusCompletedNCT01294774Phase 2
• Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE)CompletedNCT01146444Not applicable
• Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye LaserCompletedNCT00523588Phase 2
• Sunscreen RV 2457C in Photoinduced CLECompletedNCT00470912Phase 3
• Interdisciplinary Study Group of Lupus Erythematosus (ISGLE)CompletedNCT00420173
• European Society of Cutaneous Lupus Erythematosus (EUSCLE)Status unknownNCT00420121
• Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE)CompletedNCT00317681Phase 2
• Cutaneous Lupus Erythematosus and ElidelWithdrawnNCT00222183Not applicable

← Lupus Erythematosus, Cutaneous overview